WE’RE THE TRUSTED GLOBAL LEADER IN ACCESS TO MEDICINES

In becoming the trusted global leader in access to medicines, the Group has consistently delivered healthy financial returns. We believe there are several reasons to invest in Clinigen.

Unique and focused business model

We offer access to medicines at the key stages of the pharmaceutical product lifecycle by utilising Clinigen’s balanced portfolio, across the Services and Products businesses.

Disciplined corporate and product acquisitions

We have made a number of acquisitions, both of corporates to build out the infrastructure platform, and of niche hospital speciality medicines.

6

Corporate acquisitions since IPO in 2012

6

Product acquisitions since IPO in 2012



Global capability

We have built a global supply chain and distribution network, through acquisitions and partnerships, providing local market knowledge supported by global expertise.

14

International locations

128

Countries supplied in last three years

Experienced management team

We have an experienced management team both at the regional and Group level, with a track record of delivering strong growth every year since inception.

EXECUTIVE MANAGEMENT TEAM (TENURE)

Market-leading positions

We are the global leader in the management of Managed Access Programs to innovative new medicines. We are a global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials (‘IITs’).

#1

Position

Broad client and customer base

We have deep, well-established relationships with pharmaceutical and biotech companies as clients and Healthcare professionals (‘HCPs’) as customers.

577

Pharmaceutical and Biotech companies as clients

25,127

HCPs as customers*

*HCPs as customers indicates the number of registered users on Cliniport

Significant long-term growth potential

We have a significant exposure to emerging pharmaceutical growth markets from building out our infrastructure platform, service capability and product offering through a combination of organic and acquisitional growth.

ADJUSTED NET REVENUE BY REGION

Cash generative

We generate strong cash returns which are underpinned by strong credit control and working capital management.

ADJUSTED OPERATING CASH FLOW (£M)2

2. Operating cash flow is net cash flow from operating activities before income taxes and interest.